Skip to content

Ovarian Cancer Screening and AI

AI on Ovarian Cancer Screening Attitudes in Gynecologists

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07503054
Acronym
AI-OCS-Gyn
Enrollment
350
Registered
2026-03-31
Start date
2026-03-27
Completion date
2026-04-30
Last updated
2026-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ovarian Cancer Screening Recommendations by Gynecologists

Keywords

ovarian cancer screening recommendations, AI-based conversational intervention, gynecologists' knowledge on ovarian cancer screening

Brief summary

Gynecologists frequently overestimate the benefits and safety of ovarian cancer screening. AI-supported discussions may help correct these misperceptions. This study tests whether an AI-guided conversation about the evidence on ovarian cancer screening can improve gynecologists' knowledge and reduce non-evidence-based screening recommendations, compared with a control AI discussion on ovarian cancer prevalence.

Detailed description

Previous research has demonstrated that gynecologists often substantially overestimate both the effectiveness and safety of ovarian cancer screening, despite robust evidence indicating that such screening does not offer a net clinical benefit. These findings highlight the need for innovative communication strategies to support evidence-based clinical practice and reduce low value care. AI-based conversational interventions have shown promising results in other fields when aiming to correct misconceptions or encourage engagement with evidence, particularly among individuals who are initially resistant to factual information. Leveraging these insights, this study investigates whether AI-facilitated discussions can effectively improve gynecologists' knowledge of the benefit-harm profile of ovarian cancer screening and subsequently reduce non-evidence-based recommendations. The study employs a cross-sectional study design in which gynecologists who have previously indicated to regularly recommend ovarian cancer screening with transvaginal ultrasound and potentially with additional CA 125-testing to their asymptomatic, average-risk patients are randomized to one of two conditions: 1. Intervention Condition: Participants engage in an AI-guided conversation in which they explain their reasons for recommending ovarian cancer screening. The AI is instructed to address misconceptions and clarify the lack of evidence supporting a positive benefit-harm ratio. 2. Control Condition: Participants engage in an AI discussion on the prevalence of ovarian cancer, without receiving information or corrective feedback related to screening outcomes. Before and after the AI-based discussion, all participants are queried on their numerical (X out of 1,000 women) and subjective perception of ovarian cancer screening's benefits and harms and their screening recommendations. Measures are derived from instruments used in prior research. The primary objective of this study is to assess the change, from before to after the AI-based conversation, in clinicians' understanding of the benefit-harm ratio and their recommendations regarding routine ovarian cancer screening for asymptomatic, average-risk women, within and between study groups.

Interventions

BEHAVIORALChatGPT - Control

Three-turn conversation; discusses ovarian cancer risk and epidemiology; avoids screening topics; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT.

BEHAVIORALChatGPT - Evidence-Based Screening Discussion

Three-turn conversation; asks participants about screening rationale; provides evidence-based info on benefits/harms, trial data, guideline positions; concise responses (5-8 sentences). Mode of Delivery: Online chat interface; participant interacts directly with ChatGPT.

Sponsors

Charite University, Berlin, Germany
Lead SponsorOTHER
Max Planck Institute for Human Development
CollaboratorOTHER
German Research Foundation
CollaboratorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SCREENING
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
24 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* gynecologists in outpatient care who provide ovarian cancer screening to asymptomatic, average-risk women (not guideline consistent)

Exclusion criteria

* gynecologists in inpatient care * gynecologist in outpatient care who do NOT provide ovarian cancer screening to asymptomatic, average-risk women (guideline consistent)

Design outcomes

Primary

MeasureTime frameDescription
Change in intention to recommend ovarian cancer screeningImmediately post interventionDifference in participants' self-reported frequency of recommending ovarian cancer screening to average-risk women in the future after the ChatGPT interaction and their self-reported frequency of recommending the screening in the past.

Secondary

MeasureTime frameDescription
Change in benefit-harm ratio evaluation of ovarian cancer screeningsImmediately post interventionDifference between the self-reported benefit-harm ratio evaluation before and after the ChatGPT interaction.
Accuracy of knowledge regarding ovarian cancer screening evidenceImmediately post interventionParticipants' understanding of benefits, harms, and guideline recommendations for ovarian cancer screening, assessed via survey questions

Countries

Germany

Contacts

CONTACTOdette Wegwarth, Prof. Dr.
odette.wegwarth@charite.de+49 30 450 531 074
CONTACTMiriam K Rumpel, M.Sc.
miriam.rumpel@charite.de+49 30 450 531 058

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 1, 2026